ASCO Annual Meeting | Conference

Zoledronic Acid Can Be Administered Less Frequently in Breast Cancer

May 31st 2014

The dosing frequency of zoledronic acid can be reduced by 67% without compromising efficacy and safety in women with breast cancer and bone metastases.

Dr. Hussain on ETS Gene Fusions as a Predictive Biomarker in Prostate Cancer

May 31st 2014

Maha Hussain, MD, from the University of Michigan Comprehensive Cancer Center, discusses the possibility of ETS gene fusions acting as a predictive biomarker for prostate cancer.

Reducing Pills From the Cup: Discontinuing Statins in Late-Stage Cancer Patients

May 31st 2014

For patients with less than a year to live, the discontinuation of statins may increase the median time-to-death and improve quality of life.

Dr. Formenti on Concurrent Adjuvant Systemic Therapy and Accelerated Radiotherapy in TNBC

May 29th 2014

Silvia Formenti, MD, The Sandra and Edward H. Meyer Professor of Radiation Oncology chair, Radiation Oncology, NYU Langone Medical Center, associate director, Radiation Oncology, Perlmutter Cancer Center at NYU Langone, discusses a trial that examines concurrent adjuvant systemic therapy and accelerated radiotherapy in triple-negative breast cancer (TNBC)

Dr. Pavlick on a Phase II Trial of Cyclophosphamide and Ipilimumab in Melanoma

May 28th 2014

Anna C. Pavlick, DO, associate professor, Hematology and Medical Oncology, medical director, Clinical Trials Office, Perlmutter Cancer Center at NYU Langone, discusses a phase II trial exploring low-dose cyclophosphamide and ipilimumab in metastatic melanoma.

Dr. Luke Discusses the Phase III COMBI-d Trial Results

May 24th 2014

Jason J. Luke, MD, instructor, Department of Medicine, Harvard School of Medicine, staff physician, medical oncologist- melanoma, Dana-Farber Cancer Institute, discusses the controversy behind the COMBI-d trial results.

As Lung Cancer Screening Debate Continues, Study Projects Implementation Outcomes

May 14th 2014

In December 2013, the US Preventive Services Task Force (USPSTF) recommended that asymptomatic, high-risk individuals receive annual screening for lung cancer with low-dose computed tomography (LDCT).

Novel TKI May Provide New Treatment Option for Patients With Recurrent PVNS

May 14th 2014

The new targeted drug, PLX3397, has demonstrated responses in patients with pigmented villonodular synovitis (PVNS), a rare joint disorder.

For Premenopausal Women With ER-Positive Disease, Obesity Is a Major Risk Factor in Breast Cancer Mortality

May 14th 2014

Obesity significantly increases the risk of dying of breast cancer in premenopausal women with ER-positive early disease.

Delaying ADT Until Symptoms Appear Does Not Impact Survival, Study Suggests

May 14th 2014

A rising prostate-specific antigen after surgery or radiation therapy for prostate cancer is not enough reason, on its own, to initiate androgen-deprivation therapy.

AZD9291 Shows Robust Activity in Resistant EGFR-positive NSCLC

May 14th 2014

The highly selective EGFR inhibitor AZD9291 demonstrated an overall response rate of 64% without inducing dose-limiting toxicities in patients with metastatic NSCLC who harbor an acquired EGFR T790M resistance mutation.

Dr. Richard D. Carvajal on the Investigation of Selumetinib

July 25th 2013

Richard D. Carvajal, MD, medical oncologist, Memorial Sloan-Kettering Cancer Center, discusses the background of the investigation of selumetinib for advanced uveal melanoma.

Dr. Swain Discusses Studies From the 2013 ASCO Meeting

July 15th 2013

Sandra Swain, MD, medical director of the Washington Cancer Institute at MedStar Washington Hospital Center, highlights information presented at the 2013 American Society of Clinical Oncology (ASCO) Meeting.

Dr. Sartor on the Mechanism of Action of Radium-223

July 12th 2013

A. Oliver Sartor, MD, Director of the Tulane Cancer Center, describes the mechanism of action of radium-223 for bone metastases from prostate cancer.

Dr. Gogineni Comments on Oncology Drug Shortages

July 11th 2013

Keerthi Gogineni, MD, MSHP, medical oncologist, Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, comments on oncology drug shortages in the U.S.

Dr. Pardee on CPI-613 in Hematologic Malignancies

July 10th 2013

Timothy S. Pardee, MD, describes a phase I trial looking at the first-in-class mitochondrial metabolism inhibitor CPI-613 in patients with advanced hematologic malignancies.

Electra D. Paskett, PhD, on Cervical Cancer Screening

July 9th 2013

Electra D. Paskett, PhD, Professor, College of Medicine, The Ohio State University, discusses the use of vinegar as a cervical cancer screening tool in the U.S.

Dr. Bruce Roth on Curing Cancer With Immunotherapies

July 9th 2013

Bruce Roth, MD, from the Siteman Cancer Center, Washington University School of Medicine, discusses the optimism for a cure with immunotherapies.

Dr. Schuchter Discusses the Treatment of Melanoma

July 3rd 2013

Lynn M. Schuchter, MD, Chief, Hematology Oncology, Department of Medicine, University of Pennsylvania, discusses the treatment of advanced melanoma.

Dr. Gandara on the Heat Shock Protein 90 Inhibitor Ganetespib

July 1st 2013

David R. Gandara, MD, from UC Davis Cancer Center, discusses treatment with the heat shock protein 90 inhibitor ganetespib.